Description: StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers from whole blood. The company's lead product is Aristotle, a mRNA-based multi-cancer panel test for for the detection of multiple discrete cancers from a single sample of blood. It also offers ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer; Prostate Health Index, a screening test for prostate cancer; BreastSentry, a test to determine a woman's risk for developing breast cancer; and COVID-19 Tests. The company is based in Richmond Hill, Canada.
Home Page: www.stagezerolifesciences.com
70 East Beaver Creek Road
Richmond Hill,
ON
L4B 3B2
Canada
Phone:
Officers
| Name | Title |
|---|---|
| Mr. James R. Howard-Tripp | Executive Chairman & CEO |
| Dr. Choong-Chin Liew Ph.D. | Co-Founder |
| Mr. Warren Whitehead C.M.A., CPA | Chief Accountant |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.7756 |
| Price-to-Sales TTM: | 1.1599 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 40 |